Vstm3 is a Member of the CD28 Family and an Important Modulator of T-cell Function
Overview
Authors
Affiliations
Members of the CD28 family play important roles in regulating T-cell functions and share a common gene structure profile. We have identified VSTM3 as a protein whose gene structure matches that of the other CD28 family members. This protein (also known as TIGIT and WUCAM) has been previously shown to affect immune responses and is expressed on NK cells, activated and memory T cells, and Tregs. The nectin-family proteins CD155 and CD112 serve as counter-structures for VSTM3, and CD155 and CD112 also bind to the activating receptor CD226 on T cells and NK cells. Hence, this group of interacting proteins forms a network of molecules similar to the well-characterized CD28-CTLA-4-CD80-CD86 network. In the same way that soluble CTLA-4 can be used to block T-cell responses, we show that soluble Vstm3 attenuates T-cell responses in vitro and in vivo. Moreover, animals deficient in Vstm3 are more sensitive to autoimmune challenges indicating that this new member of the CD28 family is an important regulator of T-cell responses.
Shao Y, Yang W, Nanayakkara G, Saaoud F, Ben Issa M, Xu K Int J Drug Discov Pharm. 2025; 3(4).
PMID: 39926714 PMC: 11804271. DOI: 10.53941/ijddp.2024.100022.
Cui H, Elkord E Vaccines (Basel). 2025; 12(12.
PMID: 39771968 PMC: 11679306. DOI: 10.3390/vaccines12121306.
Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy.
Hosseininejad-Chafi M, Eftekhari Z, Oghalaie A, Behdani M, Sotoudeh N, Kazemi-Lomedasht F Med Oncol. 2024; 42(1):36.
PMID: 39719469 DOI: 10.1007/s12032-024-02588-y.
Revisiting T-cell adhesion molecules as potential targets for cancer immunotherapy: CD226 and CD2.
Jo Y, Sim H, Yun B, Park Y, Jin H Exp Mol Med. 2024; 56(10):2113-2126.
PMID: 39349829 PMC: 11541569. DOI: 10.1038/s12276-024-01317-9.
Zych M, Kniotek M, Roszczyk A, Dabrowski F, Jedra R, Zagozdzon R Int J Mol Sci. 2024; 25(17).
PMID: 39273326 PMC: 11395075. DOI: 10.3390/ijms25179378.